Risk adjusted net present value: What is the current valuation of AstraZeneca’s Saruparib?

Saruparib is a small molecule commercialized by AstraZeneca, with a leading Phase III program in Metastatic Prostate Cancer.

North Carolina urges HHS to license Novo and Lilly obesity drugs as a way to lower costs

Frustrated by the lack of access to expensive weight loss drugs, North Carolina officials are urging the Biden administration to negotiate licenses with the manufacturers

August 5, 2024

AbbVie inks deal for Medincell’s long-acting injectable platform worth up to $1.9B

AbbVie is betting more than $1.9 billion on a French biotech’s long-acting injectable technology. The deal gives Medincell $35 million upfront and up to $1.9

April 17, 2024

FDA offers positive signals for potential pediatric neuroblastoma drug ahead of ODAC meeting

The FDA’s Oncologic Drugs Advisory Committee tomorrow will review US WorldMeds’ potential high-risk pediatric neuroblastoma drug to reduce the risk of relapse after front-line therapy.

October 4, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.